Adjuvant Systems for Vaccines

We are an industry leader in human and veterinary vaccine adjuvants. Leveraging over 80 years of expertise, our collaborations start at all stages of the vaccine manufacturing process. Our comprehensive portfolio of immuostimulators and adjuvants accelerates the production of complete adjuvant systems. Let's create a tailored vaccine solution together. TALK TO US about sustainably sourced, non-animal derived squalene, next-generation QS 21 – based on plant tissue culture, CAF®09b which has shown promising new results for metastatic prostate cancer vaccine. Plus, PHAD™. Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells. PHAD is the first synthetic analogue of monophosphoryl lipid A (MPLA) derived from Salmonella minnesota. MPLA has been shown to be safe and effective in stimulating Th-1 type immune responses. We have many more adjuvants in our portfolio - speak with us today.